VivoSeq
Other

Demyelinating Diseases

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Demyelinating Diseases is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

2

clinical trials

Unknown status1 · 50%
Enrolling by invitation1 · 50%

Clinical Trials

Trial Activity

Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases
Unknown status·TTianjin Medical University General Hospital·N/A·NCT05414487·34 enrolled
A Study of Imaging in Demyelinating Diseases
Enrolling by invitation·MMayo Clinic·Phase 2·NCT05805839·200 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)